GlobeNewswire Clinical StudiesOriginal article
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
Phase 3positiveorelabrutinibPositive
AI Analysis
Summary
InnoCare announced publication of Phase 3 results in Science Translational Medicine demonstrating that orelabrutinib significantly prolonged progression-free survival and reduced disease progression or death risk by 68% in treatment-naïve CLL/SLL patients.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
orelabrutinib significantly prolonged progression-free survival (PFS) and reduced risk of disease progression or death by 68% in treatment-naïve CLL/SLL patients
Importance:7/10
Sentiment:
0.85
Phase 3 resultsCLL/SLLorelabrutinibpublicationprogression-free survival
Read the original article
Published by GlobeNewswire Clinical Studies on July 14, 2026 11:23 AM